What topics does this cannabis study cover?

This study covers research on: Addiction.

Where was this research published?

Published in The American journal of psychiatry on September 1, 2026.

Addiction

Why cannabis use disorder still needs better treatment options

Q: What did this Review find?

**No FDA-approved pharmacotherapy is currently available for *cannabis use disorder*.**

New Horizons in the Development of Treatments for Substance Use Disorders.

The American journal of psychiatry • September 1, 2026 • Review • Relevant

🤖

AI Summary

Substance use disorders remain a major public health challenge, and current treatment options do not meet everyone’s needs. The abstract notes that approved medications exist for alcohol, nicotine, and opioid use disorders, but no approved medications currently exist for cannabis use disorder, cocaine use disorder, or methamphetamine use disorder. Behavioral treatments also face important limits in both effectiveness and accessibility.

For people affected by cannabis use disorder, the paper highlights a significant treatment gap rather than reporting results from a new cannabis-specific therapy. It argues that future progress will likely require a broad range of approaches, including new drug classes, digital technologies, and improved ways to deliver behavioral care. The abstract reports no quantitative results, so it does not establish that any particular treatment is effective.

💡 Key Findings

No FDA-approved pharmacotherapy is currently available for cannabis use disorder.

High

90%

Existing behavioral treatments for substance use disorders have important limitations in effectiveness and accessibility.

High

80%

Future treatments may come from new medications, technologies, and delivery models, rather than a single approach.

Good

70%

📄 Original Abstract

Substance use disorders (SUDs) are a major public health problem in the United States and cause substantial morbidity and mortality. There are meaningful gaps in the available SUD treatment options, and the development of new therapies is urgently needed. While medications with U.S. Food and Drug Administration approval are available for alcohol, nicotine, and opioid use disorders, there are no approved pharmacotherapies for cannabis, cocaine, or methamphetamine use disorders. Behavioral treatments for SUDs have significant limitations in effectiveness and accessibility, and there is a need for the development of both new behavioral treatment options and new models of treatment delivery. The next generation of treatments for SUDs will likely come from a diverse set of interventions, including new drug classes, new technologies, and new methods of delivery.